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The immediate and prolonged effects of neonatal SRIH-14
treatment on pituitary somatotrophs (GH) were investigated. Female
rats were injected s.c. twice a day with 20 g of SRIH-14/100g b.w., for
five consecutive days (from 3rd to 7th day of life). Animals were
sacrificed at different life periods: at neonatal (8th day), juvenile (16th
day), peripubertal (38th day) and adult (80th day) period of life. GH cells
were studied using the peroxidase-antiperoxidase
immunocytochemical procedure. Morphometry and stereology were
used to evaluate changes in the number of GH-immunoreactive cells
per unit area, their volume and volume density. After SRIH-14 treatment,
the most prominent decrease of all measured parameters was
observed in the neonatal period. SRIH-14 induced a significant
decrease of GH cell volumes and volume densities in the juvenile,
peripubertal and adult periods of life. The number of GH-positive cells
was significantly decreased when examined immediately after
treatment, but significantly increased in adult females. Body weight,
absolute or relative pituitary weights were not affected in any of the
examined age groups. These findings suggest that neonatal SRIH-14
treatment exerts a significant immediate and prolonged inhibitory effect
on GH cells, but does not affect the growth rate in female rats.
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INTRODUCTION
The secretion of somatotrophin, or growth hormone (GH), is regulated
through a complex neuroendocrine control system that comprises two main
hypothalamic regulators, growth hormone releasing hormone (GHRH) and
somatostatin (SRIH), exerting stimulatory and inhibitory influences, respectively,
on the somatotrophic (GH) cells. Circulating GH concentrations are age-
dependent in all mammalian species studied to date. GH levels are particularly
high in the fetus and neonatal period, and decline during the juvenile period of life.
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During puberty, GH levels rise and then fall during senescence. This pattern has
been observed in rats (Rieutort, 1974; Ojeda and Jameson, 1977; Walker, et al.,
1977; Sonntag et al., 1980; Szabo and Cuttler, 1986; Welsh et al., 1986), humans
(Finkelstein et al., 1972; Rudman et al., 1981), and other mammals (Gluckman et
al., 1981). In contrast to circulating GH levels, pituitary GH concentrations are
characteristically low in the fetus, steadily increase during maturation, and then
decline later in life (Rieutort, 1974; Hu et al., 1993).
In the pituitary, SRIH inhibits GH secretion and also blocks the release of
other adenohypophyseal hormones such as thyrotrophin (TSH; Brazeau et al.,
1973) prolactin (PRL; Milo{evi} et al., 2000), gonadotrophins (Nestorovi} et al.,
2001, 2004) and in some cases, adrenocorticotropin (ACTH; Star~evi} et al.,
2000). Since its characterization in 1973 (Brazeau et al., 1973), SRIH has attracted
much attention because of its wide variety of biological functions in the nervous
and other tissues. At the periphery, SRIH is a modulator of endocrine and exocrine
functions and regulates differentiation and proliferation of normal and tumor cells
(Reichlin, 1983; Patel, 1999). Within the nervous system, SRIH acts as a
neuromodulator with physiological effects on neuroendocrine, motor and
cognitive functions (Reichlin, 1983; Epelbaum et al., 1994). Because of its ability
to inhibit many functions of various organs, its therapeutic value in clinical
conditions involving the hyperfunction of these organs, is recognized and used.
However, since SRIH has a wide variety of actions, it has been cautiously used in
pediatric cases.
We have previously shown that multiple SRIH-14 treatment decreased
morphometric parameters of GH cells in adult female rats (Milo{evi} et al., 2002).
The aim of this study was to investigate whether multiple neonatal SRIH-14
treatment has immediate or/and prolonged effects on pituitary GH cells in female
rats.
MATERIAL AND METHODS
Animals. Time-mated pregnant Wistar rats were housed individually and
maintened in a controlled environment (12h light : 12 h dark; 22 ± 2 oC), with food
(produced by Veterinarski zavod Subotica, Subotica, Sebia) and water at libitum.
Female pups were injected s.c. twice a day (8 AM and 8 PM) with 20 g of SRIH-14
(S9129, Sigma, St. Louis, Mo., USA) per 100g b.w., for five consecutive days (3rd
to 7th days of life; neonatal SRIH-14 treatment). The dose regimen selected for
SRIH-14 was based on Rebuffat et al. (1984) and modified for administration every
12 h instead of every 8 h. Control female pups s.c. received the equivalent volume
of saline by the same schedule. Animals were sacrificed at 8 AM at different
periods of life: at neonatal (8th day), juvenile (16th day), peripubertal (38th day) and
adult (80th day) period of life. Every age group comprised five females.
Experimental protocols were approved by the Local Animal Care Committee and
conformed to the recommendations given in "Guide for the Care and Use of
Laboratory Animals" (1996, National Academy Press, Washington D.C.)
Immunocytochemistry. The pituitaries were removed immediately after
sacrifice and fixed in Bouin's solution for 48 hours at room temperature. After
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dehydration in an ethanol gradient, organs were embedded in paraffin. Series of
seven sections (5 m) of the pituitary cut through three tissue levels (dorsal,
middle and ventral portion) of the pars distalis were used for immunostaining. For
the localization of pituitary somatotrophs the peroxidase-antiperoxidase method
was used (Sternberger, 1970). After deparaffinization and rehydration of sections,
endogenous peroxidase activity was blocked by incubation in methanol
containing 0.3% H2O2 for 15 minutes at room temperature, followed by rinsing in
0.1 M phosphate buffered saline (PBS; pH 7.4) for 5 minutes. The non-specific
background staining was reduced by incubation with non-immune serum, i.e.
normal porcine serum diluted 1:10 with PBS for 45 minutes. The sections were
than incubated overnight with primary antibodies (hGH antisera - DAKO A/S,
Glostrup, Denmark) diluted with PBS 1:300. Subsequent to a 5 minute rinse in
PBS, the sections were incubated with secondary antibody (1:500 swine-anti-
rabbit IgG, 45 min; DAKO A/S, Glostrup, Denmark), rinsed for 5 minutes in PBS,
incubated with rabbit-antiperoxidase serum (1:100; 45 min; DAKO A/S, Glostrup,
Denmark) and again rinsed in PBS. The antigen-antibody complex was visualized
by incubating the sections with chromogen substrate, 0.05% 3,3-
diaminobenzidine (DAB; Serva, Heidelberg, Germany) and 0.03% H2O2. The
incubated sections were counterstained with haematoxylin. Control sections were
incubated with normal porcine serum without primary antisera.
Stereological measurements. Immunocytochemically stained sections of
pituitaries cut through three tissue levels of the pars distalis were used for the
morphometric examinations of GH immunoreactive cells with visible nuclei. The
cell volume of GH cells (Vc) and their volume densities (VV) were estimated under
light microscope at 1000X magnification using the M42 multipurpose test system
(Weibel, 1979). The volumes of GH-positive cells were expressed in m3, while
their volume densities were given as percentages of total pituitary cells in mm3. At
the same time, the number of immunoreactive cells per unit area (mm2) in each
section was analyzed.
Statistical analyses. The data obtained for each group were averaged and
the standard deviation was calculated. A one-way analysis of variance (ANOVA),
followed by multiple range test of Duncan was used for statistical comparisons of
the differences between groups. A probability value of 5% or less was considered
statistically significant.
RESULTS
Somatotrophic (GH) cells of the control females in all examined age groups
were strongly immunocytochemically stained. They were polygonal, oval or
polyhedral in shape with prominent, often eccentrically located nuclei. GH-
positive cells were grouped and positioned throughout the pituitary pars distalis,
often in close contact with the blood capillaries (Figs. 1a-d). It has been noted that
GH cells of adult females were larger, with more homogenously immunostained
cytoplasm compared to the earlier periods of life (Figs. 1a-d). After neonatal SRIH-
14 treatment GH cells were smaller in all examined age groups (Figs. e-h). In the
pituitaries of neonatal females GH-positive cells were smaller in size and fewer in
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Figure 1. Immunoreactive GH cells (arrows) in pituitary pars distalis in control (a-d) and
female rats after neonatal SRIH-14 treatment (e-h) of neonatal (a, e), juvenile (b, f),
peripubertal (c, g) and adult (d, h) period of life
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Figure 2. a) The number (No) of immunoreactive GH cells per unit area (mm2) in control (C)
and female rats after neonatal SRIH-14 treatment; b) The cellular (Vc) volume (m3)
of GH-immunopositive cells of control (C) and female rats after neonatal SRIH-14
treatment; c) Volume density (VV) of immunoreactive GH cells expressed as a
percentage (%) of total adenohypophyseal cells volume in control (C) and female rats
after neonatal SRIH-14 treatment. All values are given as means ±SD. ap<0.05 vs.
control from previous period of life; bp<0.05 vs. corresponding control
number. Their cytoplasm was more intensely immunostained than in the neonatal
controls, forming a thin ring around the nuclei (Fig. 1e). The cytoplasm of GH-
positive cells in the pituitaries of peripubertal and adult females was weakly
immunstained (Figs. 1g-h).
The number of GH-immunopositive cells per unit area (mm2) in the
pituitaries of control females did not change from neonatal until the juvenile
period, but decreased thereafter from juvenile until the adult period of life (Fig 2a).
The volume of GH cells increased during the investigated periods. The most
prominent increase (by 64.7%; p<0.05) was observed from the peripubertal until
the adult period of life (Fig. 2b). In the same period the volume density of GH cells
increased by 48.4% (p<0.05; Fig. 2c).
After neonatal SRIH-14 treatment the number of GH-immunoreactive cells
per unit area was markedly decreased in 8-day old females (by 56.2%; p<0.05) in
comparison to the neonatal controls. In 16 and 38 days old neonataly treated
females, this parameter was similar to the values of corresponding controls.
However, in adult females the number of GH-immunopositive cells was by 25.7%
(p<0.05) higher than in adult controls (Fig. 2a).
Stereological analysis showed that the neonatal SRIH-14 treatment
significantly decreased the volume of GH cells in all examined age groups (Figs.
2b, c). In the neonatal, juvenile and peripubertal periods of life, this parameter was
decreased by 33.5%, 38.5%, 17.1%, respectively, when compared to the
corresponding controls. The most prominent decrease of GH cell volume was
noted in the adult age group (by 53.8%; p<0.05).
Table 1. Body weight, absolute and relative pituitary weight of control (C) and
female rats at different periods of life after neonatal SRIH-14 treatment
Groups Body weight(g)
Absolute pituitary
weight (mg)
Relative pituitary
weight (mg%)
Neonatal
C 17.8 ± 0.7 2.0 ± 1.0 11.2 ± 5.4
SRIH-14 16.1 ± 1.8 1.8 ± 0.8 11.6 ± 5.3
Juvenile
C 27.2 ± 0.4 2.5 ± 0.6 9.2 ± 2.0
SRIH-14 22.9 ± 2.0 2.4 ± 0.9 10.3 ± 3.8
Peripubertal
C 117.4 ± 8.6 5.6 ± 0.9 4.8 ± 0.8
SRIH-14 130.0 ± 0.7 5.4 ± 1.1 4.2 ± 0.9
Adult
C 255.0 ± 20.7 11.8 ± 2.3 4.6 ± 0.7
SRIH-14 232.5 ± 20.5 11.6 ± 1.3 5.0 ± 0.3
All values are given as means ± SD.
The percentage of GH cells per unit volume (mm3) of total pituitary gland
tissue, i.e. the volume density, was also significantly reduced by neonataly
applied SRIH-14 (Fig. 2c). The most prominent decrease in volume density of GH
cells was observed when examined immediately after treatment (by 67.6%;
p<0.05). In the juvenile, peripubertal and adult periods of life, the percentages of
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GH cells were reduced by 22.0%, 25.8% and 26.1%, respectively, compared to
corresponding controls.
Neonatal SRIH-14 treatment did not induce any significant changes in body
weight, absolute or relative pituitary weights in female rats at any age group (Table
1).
DISCUSSION
The results of this study demonstrated that neonataly applied SRIH-14 had
immediate and prolonged inhibitory effects on pituitary GH cells. The most
prominent inhibitory effect was noticed immediately after SRIH-14 treatment, in
the neonatal period of life.
Circulating GH levels are elevated in neonatal rats (Rieutort, 1974). Several
in vivo and in vitro studies indicated that the reason is low responsiveness of
neonatal pituitary to somatostatin, due to low numbers of its receptors (Khorram
et al., 1983; Rieutort, 1981; Cuttler et al., 1986). However, Reed et al. (1999)
reported that the neonatal rat pituitary expresses the same complement of
somatostatin receptors (sstr 1-5) as the adult pituitary. The same authors found
that the expression of sst2 mRNA was age dependent. Levels of sst2 mRNA were
low in pituitaries 2-day-old animals, but thereafter rose progressively until
adulthood. However, pituitaries of neonatal animals expressed sst1, sst3, sst4,
and sst5 mRNA with no significant ontogenic changes in expression of these
subtypes. SRIH-14, used in our study, is known to bind to all five somatostatin
receptors with high affinity (Patel, 1999), and therefore had the opportunity to
directly affect GH cells in the neonatal period of life.
The possibility of indirect influence of SRIH on GH cells, through the
inhibition of hypothalamic GHRH, should be taken into consideration. Thoss et al.
(1995) demonstrated the expression of sstr 1, 3, 4, and 5 in the arcuate
hypothalamic nucleus of 5 day old rats. Cella et al. (1990) reported a significant
(about 40%) reduction in GH cell percentage in the pituitaries of neonatal rats after
passive immunization against endogenous GHRH. However, they also reported a
significant recovery 30 and 60 days after treatment.
In the pituitaries of control female rats, GH cell number per unit area slightly
descended from the neonatal period of life up to adulthood, due to the growing
blood vessels and connective tissue in the pituitaries. The volume of GH cells, on
the other hand, increased with age, which resulted in the increase of the
percentage of GH cells in the pituitary. The most prominent increase was noted
from the peripubertal up to the adult period of life. Takahashi (1991) also reported
the increase of GH cell percentage in the pituitaries of female rats from 30 to 60
days of age, when the growth rate was increasing (Chowen et al., 1993). In our
experimental conditions, in SRIH-14 treated females, this increase of GH cell
volume was not observed. On the contrary, the GH cell volumes at all age groups
were similar to the ones found in the pituitaries of treated females examined
neonataly. Therefore, comparing to the corresponding control, the most
prominent decrease of GH cell volume was noted in the adult period of life.
However, an attempt of normalization of the percentage of GH cells in time was
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observed. Namely, a significant increase in number of GH cells per unit area in
adult females neonataly treated with SRIH-14 was noted. When compared to the
corresponding controls, this parameter increased about 25%. Combined with a
50% decrease in GH cell volume, it resulted in about 25% decrease in the
percentage of GH cells in the pituitary.
The pituitary responds to physiological demands by modifying hormone
synthetic and secretory activity, and by altering the relative proportions of different
cellular subtypes that it contains (Nolan et al., 2004). Formation of new hormone-
producing cells involves mitosis of differentiated cells, and maturation of
undifferentiated cells. It has been shown that adult mice pituitary contains
stem/progenitor cells that may function as "source" cells for new hormone-
producing cells (Chen et al., 2005). In addition, Taniguchi et al. (2002) reported
that about 10% of all proliferating cells in the pituitary are already differentiated
cells. This percentage for GH cells is 30-40% at most, suggesting a very active
production.
Neonatal SRIH-14 treatment did not affect body weight, absolute or relative
pituitary weights in any examined age groups. In rats and mice the critical period
of GH effect on weight begins in the second postnatal week (Rodier et al., 1990).
GH cells of neonataly treated peripubertal and adult females were smaller, but
their cytoplasm was weakly immunostained suggesting increased hormone
secretion. Combined with a significant increase of GH cell number in the adult
period, it can be assumed that circulating GH levels were not reduced when
compared to the corresponding controls.
On the basis of our results we can conclude that neonatal application of
SRIH-14 to neonatal female rats exerts a significant immediate and prolonged
inhibitory effect on GH cells, but does not affect the growth rate from neonatal
period of life up to adulthood.
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NEONATALNO APLIKOVAN SOMATOSTATIN IMA NEPOSREDAN I ODLO@EN
INHIBITORNI UTICAJ NA GH ]ELIJE HIPOFIZE
NESTOROVI] NATA[A, TERZI] MILICA, NEGI] NATA[A, STAR^EVI] VESNA
i MILO[EVI] VERICA
SADR@AJ
Ispitivan je neposredan i odlo`en efekat neonatalnog tretmana somatostati-
nom (SRIH-14) na somatotropne (GH) }elije. @enke pacova su dva puta dnevno
s.c. tretirane sa 20 g SRIH-14/100g t.m. u toku pet dana (od 3. do 7. dana `ivota) i
`rtvovane u razli~itim periodima `ivota: u neonatalnom (8. dan), juvenilnom (16.
dan), peripubertalnom (38. dan) i adultnom (80. dan) periodu. GH }elije su imu-
nocitohemijski obele`ene metodom peroksidaza-antiperoksidaza a morfo-
metrijskim i stereolo{kim metodama odre|ivani su broj GH }elija po jedinici
povr{ine, njihov volumen i volumenska gustina. Nakon somatostatinskog tret-
mana, najzna~ajnije smanjenje svih merenih parametara utvr|eno je u neonatal-
nom periodu. SRIH-14 je izazvao zna~ajno smanjenje volumena i volumenske
gustine GH }elija u juvenilnom, peripubertalnom i adultnom periodu `ivota. Broj
GH-pozitivnih }elija po mm2 je bio zna~ajno smanjen kada je ispitivan nepo-
sredno nakon tretmana, ali je bio zna~ajno pove}an kod adultnih `enki. Telesna
masa, kao i apsolutne i realtivne mase hipofiza nisu bile izmenjene ni u jednoj od
ispitivanih starosnih grupa. Dobijeni rezultati ukazuju da neonatalni tretman so-
matostatinom izaziva zna~ajan neposredan i odlo`en inhibitoran uticaj na GH
}elije, ali ne uti~e na stopu rasta kod `enki pacova.
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